Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (241)	9/10/2000 12:02:24 PM
From: tom pope	Respond to of 1833

I don't get it either, and would need a CPA to work out the math. This from the 10-k At December 31, 1999, the Company had tax net operating loss carryforwards of approximately $30.7 million and research and development credit carryforwards of approximately $2.6 million which expire in years 2009 through 2019. The Company's ability to utilize such net operating loss and research and development credit carryforwards is subject to certain limitations due to ownership changes as defined by rules enacted with the Tax Reform Act of 1986. I can't reconcile that to your figures unless the carryforwards are reduced by the tax rate. Don't see how the the litigation reserve becomes a deferred tax asset unless the assumption is that the company will lose the patent dispute, and the amount will be subsumed under operating loss. The deferred tax asset might make the company attractive to an acquiror, but I do recall that the utilization of tax loss carryforwards is subject to considerable limitations.